drugset / Trial / NCT03291418

To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

NCT03291418

Phase 1/2 Completed 258 enrolled Antibe Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Timeline

Start
2017-09-08
Primary completion
2018-03-31
Completion
2018-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ATB-346 Small molecule 250 mg Oral
Comparator Naproxen Small molecule 550 mg Oral

Indications